Long-Term Efficacy of Guselkumab on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through Two Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Biologic-Naïve Patients With Psoriatic Arthritis

    Dafna D. Gladman, Michael Starr, Roberto Ranza, Ana-Maria Bravo Perdomo, Marcie Strauss, M. Shawi, Chenglong Han
    Studysummary Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →